Boceprevir

Drug Profile

Boceprevir

Alternative Names: SCH-503034; Victrelis

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Imino acids; Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In adolescents, In children) in Germany (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In adolescents, In children) in Poland (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In adolescents, In children) in Spain (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top